Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ: AXSM )

121.65 +2.20 (+1.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 429,248
Open 119.59
Bid (Size) 118.09 (1)
Ask (Size) 125.82 (1)
Prev. Close 119.45
Today's Range 118.10 - 122.86
52wk Range 64.11 - 139.13
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+39.32%
+39.32%
1 Month
-4.27%
-4.27%
3 Month
+24.46%
+24.46%
6 Month
+33.64%
+33.64%
1 Year
+75.31%
+75.31%

More News

Read More
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
Via Benzinga
Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock
Via Benzinga
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
Via Benzinga
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride
Via Stocktwits
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?
Via Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Via Benzinga
Exposures Product Safety
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Axsome Therapeutics Revenue Surges 66%
Via The Motley Fool
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Via Benzinga
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
Via The Motley Fool
Earnings Scheduled For February 18, 2025
Via Benzinga
Why Axsome Therapeutics Stock Is Soaring Today
Via The Motley Fool
Why Axsome Therapeutics Stock Is Skyrocketing Today
Via The Motley Fool
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
Via Benzinga
Axsome Stock Rockets To Record High After Settling With Teva Over Depression Drug, Retail Optimism Swells
Via Stocktwits
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.